An oncology biotech advancing its lead asset into a pivotal Phase III study for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) faced a significant operational challenge. They had to scale from early phase into a global program spanning ~160 sites across 15 countries. With limited infrastructure outside the U.S. and intense competition for investigators, sites, and eligible patients, the sponsor needed an experienced global CRO partner that could accelerate startup while building the site engagement needed to sustain enrollment momentum.
Worldwide Clinical Trials developed a coordinated global strategy centered on targeted site selection, study differentiation, high-touch partnership, and regulatory and startup execution. The approach delivered early momentum across North America, Europe, and Asia-Pacific, with more than 60 sites activated within four months of the first activation. This allowed regulatory approvals one month ahead of schedule, and the first patient enrolled approximately four weeks ahead of plan. Enrollment subsequently reached more than twice the expected level at the reported milestone, even before the full global footprint was active.
Read the full case study to learn how strategic feasibility and site selection helped position a 570-patient Phase III study to compete for investigators and patients in a crowded first-line PDAC landscape.